Syngene International posted a net loss of ₹9 crore for the first quarter of FY27, compared to a profit of ₹87 crore in the same period last year. Revenue declined by 16% to ₹736 crore, driven by lower demand from a major biologics client and unfavorable foreign exchange movements. Investors are monitoring the management's recovery plan for the second half of the fiscal year.
Syngene International, a key player in contract research and manufacturing, faced a difficult start to the current fiscal year. For the quarter ending June 2026, the company reported a net loss of ₹9 crore, a stark contrast to the ₹87 crore profit it earned during the same period in the previous year. The decline reflects significant hurdles in both revenue growth and operational profitability.
Revenue and Margin Pressure
Operational revenue dropped 16% year-on-year, landing at ₹736 crore. The company also experienced a major impact on its operating profitability, with EBITDA (earnings before interest, tax, depreciation, and amortization) falling 56% to ₹91 crore. As a result, the EBITDA margin contracted sharply to 12%, down from the 24% margin reported in the first quarter of the prior year. The company noted that an exceptional charge related to employee termination benefits further weighed on the bottom line.
Factors Impacting Performance
Management identified two main problems behind these results: reduced demand from a key client in the biologics segment and losses from foreign exchange hedging. These factors created immediate pressure on the company's financial performance. While Syngene has started cost-saving initiatives to help manage expenses, the current quarter highlights the vulnerability of contract research firms when major clients reduce their spending or off-take.
Outlook and Strategic Focus
Despite the weak performance, Syngene leadership remains focused on a recovery in the second half of the fiscal year. The company has shared a target of a single-digit revenue decline for the full year and expects EBITDA margins to recover toward the mid-20s. Under the leadership of Managing Director and CEO Siddharth Mittal, the company is prioritizing better commercial execution and a more cost-competitive structure.
Syngene is continuing to invest in its CDMO (Contract Development and Manufacturing Organization) capabilities and AI-driven platforms, such as its Syn.AI tool, to improve service offerings. Additionally, the company is pursuing strategic partnerships, including a recent memorandum of understanding with BRIC-THSTI, to expand its reach in clinical and translational research.
For investors, the key monitorable will be whether the company can successfully ramp up revenue and restore margins in the coming quarters. The effectiveness of the cost-optimization measures and the stabilization of demand from its large client base will be critical to watch in future quarterly filings.